ArticleCancer chemotherapy and pharmacology2026
Ototoxicity beyond platinum-based derivatives.
Article in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOtotoxicity caused by chemotherapy is a growing problem. Literature highlights the effects of platinum compounds. However, other chemotherapy drugs also have demonstrated audiological changes. The objective of this study was to compare pre- and post-treatment distortion product otoacoustic emissions (DPOAEs) in adult patients undergoing different chemotherapy regimens.
methodsCohort study comprising 174 individuals receiving chemotherapy (CT) between April 2022 and December 2023. DPOAE were evaluated in all patients at 2 kHz, 4 kHz, 6 kHz, 8 kHz, 10 kHz, and 12 kHz, before initiating chemotherapy and after completing the treatment. For differential analysis, the protocols were grouped into CT with platinum-based agents and other protocols.
resultsA reduction in response in at least one frequency of the DPOAE test was observed in 79% of the patients. 81% of those who received CT without platinum derivatives exhibited alterations in post-treatment examinations, whereas in the group with platinum-based compounds, alterations were observed in 79% of the subjects. Different percentages of response deterioration were observed across frequencies: 27.6% at 2 kHz, 24.6% at 4 kHz, 41.2% at 6 kHz, 58.8% at 8 kHz, 57.4% at 10 kHz, and 72.4% at 12 kHz. The ototoxic effect of chemotherapy protocols, with and without platinum, was more pronounced at higher frequencies, with no statistically significant difference between the groups.
conclusionChemotherapy has shown signs of ototoxicity through changes in DPOAEs in the sample studied. The ototoxic effects were similar between drug protocols with and without platinum, highlighting the need for audiological monitoring in all chemotherapy patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.